Article thumbnail

Current Status and Future Perspectives on the Etiology of Esophageal Adenocarcinoma

By Aaron P. Thrift, Nirmala Pandeya and David C. Whiteman


Esophageal adenocarcinoma is the most common type of esophageal cancer in most Western countries and is an important contributor to overall cancer mortality. Most cases of esophageal adenocarcinoma are believed to arise from Barrett’s esophagus. Esophageal adenocarcinoma occurs more frequently in white men over 50 years old, as well as in people with frequent symptoms of gastroesophageal reflux, in smokers and in people who are obese. Higher consumption of fruit and vegetables, use of non-steroidal anti-inflammatory drugs, and infection with Helicobacter pylori have all been shown to reduce the risk of esophageal adenocarcinoma. Here, we review the epidemiological evidence for the major risk factors of esophageal adenocarcinoma and also discuss perspectives for future research

Topics: Oncology
Publisher: Frontiers Research Foundation
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2010). A comprehensive survey of clonal diversity measures in Barrett’s esophagus as biomarkers of progression to esophageal adenocarcinoma.
  2. (2005). A systematic review and meta-analysis of the sex ratio for Barrett’s esophagus, erosive reflux disease, and nonerosive reflux disease.
  3. (2008). Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol. Biomarkers Prev.
  4. (2005). Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk?
  5. (1972). Adenocarcinomaof theoesophagus: incidence and survival rates in New South Wales,
  6. (2011). Alcohol intake and risk of esophageal adenocarcinoma: apooledanalysisfromtheBEACON Consortium.
  7. (2009). Alcohol types and sociodemographic characteristics as risk factors for Barrett’s esophagus.
  8. and Anandasabapathy,S.(2009).Exploring the association between elevated body mass index and Barrett’s esophagus: a systematic review and meta-analysis.Ann.Thorac.Surg.87,
  9. (2009). and foods and esophageal cancer risk: a systematic review.
  10. (2000). Association between medications that relax the lower esophageal sphincter and riskforesophagealadenocarcinoma.
  11. (2010). Association of Helicobacter pylori infection with reduced risk for esophageal cancer is independent of environmental and genetic modifiers.
  12. (2006). Barrett’s esophagus and medications that relaxtheloweresophagealsphincter.
  13. (1989). Barrett’s esophagus: development of dysplasia and adenocarcinoma.
  14. (2008). Barrett’s esophagus: incidence and prevalence estimates in a rural mid-western population.
  15. (2002). Barrett’s esophagus.
  16. (2011). Cancer Facts and Figures
  17. (2008). Cancers of the esophagus and carbonated beverage consumption: a population-based casecontrolstudy.CancerCausesControl 19,
  18. (2006). Carbonated soft drinks and risk of esophageal adenocarcinoma: a population-based casecontrolstudy.J.Natl.CancerInst.98,
  19. (2006). Carbonatedsoftdrinkconsumptionand risk of esophageal adenocarcinoma.
  20. (2007). Central adiposity and risk of Barrett’s esophagus.
  21. (2011). Changes in prevalence, incidence and spontaneous loss of gastrooesophageal reflux symptoms: a prospective population-based cohort study, the HUNT study.
  22. (2010). Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON
  23. (2009). Cigarette smoking and the risk of Barrett’s esophagus.
  24. Coadaptation of Helicobacter pylori and humans: ancient history, modern implications.
  25. (2008). Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus.
  26. (2006). Continuous treatment of Barrett’s oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
  27. (2009). Current and past smoking significantly increase risk for Barrett’s esophagus.
  28. (2012). Current status and future perspectives on the etiology of esophageal adenocarcinoma.
  29. (2011). Dating the rise of esophageal adenocarcinoma: analysis of Connecticut Tumor Registry data, 1940–2007. Cancer Epidemiol. Biomarkers Prev.
  30. (2010). Dietary antioxidant and mineral intake in humans is associated with reduced risk of esophageal adenocarcinomabutnotrefluxesophagitis or Barrett’s esophagus.
  31. Dietary patterns and the risk of Barrett’s esophagus.
  32. (2008). E.,and LaVecchia,C.
  33. (2010). Eating habits and risk of esophageal cancers: a population-based casecontrolstudy.CancerCausesControl 21,
  34. (2009). Effectsofdietaryfiber,fats,andmeat intakesontheriskofBarrett’sesophagus.
  35. (2007). Epidemiology and pathogenesis of esophageal cancer.
  36. (2010). Epidemiology of esophageal adenocarcinoma
  37. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN
  38. (2005). Ethnicity, gender, and socioeconomic status as risk factors foresophagitisandBarrett’sesophagus.
  39. (2007). Fiber intake and risk of adenocarcinomas of the esophagus and stomach.
  40. (2000). Gastroesophageal reflux disease, use of H-2 receptor antagonists, and risk of esophageal and gastric cancer.
  41. (2009). Glycemic index, carbohydrate and fiber intakes and risk of reflux esophagitis, Barrett’s esophagus, and esophageal adenocarcinoma.
  42. (2008). Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev.
  43. (2011). Helicobacter pylori infection and the risks of Barrett’s oesophagus: a populationbasedcase-controlstudy.Int.J.Cancer. doi: 10.1002/ijc.26242. [Epub ahead of print].
  44. (2008). Helicobacter pylori infectionandtheriskof Barrett’soesophagus:a community-based study.
  45. (2004). Helicobacter pylori persistence: biology and disease.
  46. (2011). Incidence of adenocarcinoma among patients with Barrett’s esophagus.
  47. (2008). Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age.
  48. (1988). Incidence of cancer of the esophagus in the United States by histologic type.
  49. (2010). incidence: are we reaching the peak? Cancer Epidemiol.
  50. (2005). Increasing incidence of Barrett’s oesophagus in the general population.
  51. (1997). Increasing incidence of Barrett’s oesophagus: education, enthusiasm, or epidemiology?
  52. (2007). Inflammation and oxidative stress in gastroesophageal refluxdisease.J.Clin.Biochem.Nutr.
  53. (2008). Leptin and the risk of Barrett’s oesophagus.
  54. (2000). Leptin production in adipocytes from morbidly obese subjects: stimulation by dexamethasone, inhibition with troglitazone, and influence of gender.
  55. (2007). Leukocyte telomere length predicts cancer risk in Barrett’s esophagus. Cancer Epidemiol. Biomarkers Prev.
  56. (2011). Lifetime alcohol consumption and risk of Barrett’s esophagus.
  57. (2007). mass index as risk factors for Barrett’s esophagus.
  58. (2002). Medicalprogress:Helicobacterpylori infection.
  59. (2009). Medication usage and the risk of neoplasia in patients with Barrett’s esophagus.
  60. (2007). Meta-analysis of antioxidant intake and the risk of esophageal and gastric cardia adenocarcinoma.
  61. (1998). Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer.
  62. (2010). Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux.
  63. (2007). Nitric oxideandacidinducedouble-strand DNA breaks in Barrett’s esophagus carcinogenesis via distinct mechanisms.
  64. (2012). Non-steroidal anti-inflammatory drug use reduces risk for adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology. doi: 10.1053/j.gastro.2011.11.019. [Epub ahead of print].
  65. (2006). Non-steroidal anti-inflammatory drugs, lower oesophageal sphincter-relaxing drugs and oesophageal cancer: a case-control study.
  66. (2005). Non-steroidal antiinflammatory drugs and risk of neoplastic progression in Barrett’s oesophagus: a prospective study.
  67. (2006). Nonsteroidal anti-inflammatory drugs and the esophageal inflammationmetaplasia-adenocarcinoma sequence.
  68. (2001). Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol. Biomarkers Prev.
  69. (2009). Oesophageal cancer incidence in the United States by race, sex, and histologic type,
  70. (1991). Only patients with dysplasia progress to adenocarcinoma in Barrett’s oesophagus.
  71. (2011). paper pending published: 20
  72. (2001). Predictors of progression in Barrett’s esophagus III: baseline flow cytometric variables.
  73. Prevalence of Barrett’s esophagus in the general population: an endoscopic study.
  74. (1990). Prevalence of columnarlined (Barrett’s) esophagus. Comparison of population-based clinical and autopsy findings.
  75. (2003). Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis.
  76. (2004). Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett’s esophagus.
  77. (2004). Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett’s oesophagus.
  78. (2009). Race,ethnicity,sex and temporaldifferencesinBarrett’soesophagus diagnosis: a large communitybased study,
  79. (2004). Re: cost-effectiveness of aspirin chemoprevention for Barrett’s esophagus.
  80. (2001). Regulation of leptin production.
  81. (2007). Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis.
  82. (2008). Relationship between Helicobacter pylori infection and gastric atrophy and the stages of the oesophageal inflammation, metaplasia, adenocarcinoma sequence: results from the FINBAR case-controlstudy.Gut 57,734–739.
  83. (2007). Risk factors for Barrett’s oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. W o r l dJ .G a s t r o e n -terol.
  84. (2007). Risk factors for Barrett’s oesophagus: a population-based approach.
  85. Risk of Barrett’s oesophagus, oesophageal adenocarcinoma and reflux oesophagitis and the use of nitrates and asthma medications.
  86. Risk of esophageal adenocarcinoma and mortality in patients with Barrett’s esophagus: a systematic review and meta-analysis.
  87. (1998). Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medicationsthatpromotegastroesophageal reflux.CancerEpidemiol.Biomarkers Prev.
  88. Screening for Barrett’s esophagus in colonoscopypatientswithandwithoutheartburn.Gastroenterology 125,
  89. (2010). Serum leptin and adiponectin levels and risk of Barrett’s esophagus and intestinal metaplasia of the gastroesophageal junction.
  90. (2006). Temporal changes in the endoscopic frequency of new cases of Barrett’s esophagus in an Australian health region. A m .J .G a s -troenterol.
  91. (2009). The association between alcohol and reflux esophagitis,Barrett’sesophagus,and esophageal adenocarcinoma.
  92. (2011). The impact of obesity on the rise in esophageal adenocarcinoma incidence: estimates from a disease simulation model. Cancer Epidemiol.
  93. (2010). The prevalence of Barrett’s esophagus in the US: estimates from a simulation model confirmed by SEER data.
  94. (1995). The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia.
  95. (2011). The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett’s oesophagus.
  96. (2005). Theroleof overdiagnosisandreclassification in the marked increase of esophageal adenocarcinoma incidence.
  97. This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.
  98. (2008). Three-tiered risk stratification model to predict progressioninBarrett’sesophagususingepigenetic and clinical features.
  99. (2002). Time trends incidence of both major histologic types of esophageal carcinomas in selected countries,
  100. (2012). Tobacco smoking increases the risk of high-grade dysplasiaandcanceramongpatients with Barrett’s esophagus.
  101. (2000). Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries.
  102. (2007). Use of anti-inflammatory drugs and lower esophageal sphincter-relaxing drugs and risk of esophageal and gastric cancers.
  103. (2009). Vegetable and fruit intakes and risk of Barrett’s esophagus in men and women.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.